Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
Portfolio Pulse from Vandana Singh
Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc (NASDAQ:CRVS) with an Outperform rating and a price target of $7.00. The company plans to expand soquelitinib trials into larger oncology indications, including clear cell renal cell carcinoma. Corvus Pharmaceuticals revealed updated data from the Phase 1/1b trial evaluating single-agent therapy with CPI-818 in patients with relapsed T cell lymphomas. The company's cash reserve of $37 million is expected to fund operations until mid-2024.
August 18, 2023 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corvus Pharmaceuticals has received an Outperform rating from Oppenheimer, with a price target of $7.00. The company is planning to expand its soquelitinib trials, which could potentially boost its stock.
The positive rating from Oppenheimer, along with the company's plans to expand its soquelitinib trials, could potentially attract more investors, leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100